A Case of Hyperthyroidy Developing in “Pegylated-Interferon” Therapy

Mehmet Aslan; Yasar Nazlıgul; Nurten Aksoy; Nevin Yılmaz
May 2007
Digestive Diseases & Sciences;May2007, Vol. 52 Issue 5, p1194
Academic Journal
No abstract available.


Related Articles

  • Peginterferon-α.  // Reactions Weekly;8/4/2007, Issue 1163, p21 

    The article describes a case of abducens palsy and Sjogren's syndrome in a 65-year-old man with renal cancer induced by pegylated interferon therapy. An overview of the symptoms developed by the patient consistent with abducens palsy and Sjogren's syndrome is presented. His diplopia improved and...

  • Peginterferon-α-2a.  // Reactions Weekly;7/23/2011, Issue 1361, p33 

    The article discusses the case of a male patient with chronic hepatitis B who developed facial hyperpigmentation during pegylated interferon alpha therapy, published in the January-March 2011 issue of "Acta Gastro-Enterologica Belgica."

  • Abducens polsy and Sjögren's syndrome induced by pegylated interferon therapy. Oishi, Akio; Miyamoto, Kazuaki; Kashii, Satoshi; Yoshimura, Nagahisa // British Journal of Ophthalmology;Jun2007, Vol. 91 Issue 6, p843 

    A letter to the editor about a case of woman who has an abducens palsy and Sjögren's syndrome induced by pegylated interferon therapy is presented

  • Peginterferon-α-2a/ribavirin.  // Reactions Weekly;11/12/2011, Issue 1377, p30 

    The article mentions the case of autoimmune hepatitis and Graves' disease during pegylated Interferon-2a and ribavirin therapy.

  • Successful Treatment of Disseminated Human Papillomavirus Infection with Pegylated Interferon and Ribavirin. Shrestha, Nabin K.; Hamrock, David J. // Clinical Infectious Diseases;7/1/2010, Vol. 51 Issue 1, pe4 

    We report a case of disseminated human papillomavirus infection that developed in a patient while receiving efalizumab for the treatment of psoriasis. This infection progressed for several months after efalizumab treatment had been stopped. All human papillomavirus lesions completely resolved...

  • Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy. Chopra, Amit; Marak, Creticus; Alappan, Narendrakumar; Shim, Chang // Case Reports in Pulmonology;1/29/2015, Vol. 2015, p1 

    Hepatitis C virus infection is the leading cause of chronic liver disease in the United States of America. Pegylated interferon α and ribavirin combination is the mainstay of treatment. Severe pulmonary toxicities are rarely reported. We report here a case of severe form of organizing...

  • Peginterferon-α-2a.  // Reactions Weekly;1/19/2008, Issue 1185, p25 

    The article describes a case of severe stomatitis induced by treatment with pegylated-interferon alpha-21 and ribavirin in a 42-year-old man with hepatitis C infection. Twenty-eight days following the initiation of treatment with pegylated-interferon alpha-21 and ribavirin, the patient developed...

  • Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report. Weimin Jiang; Hisashi Hidaka; Takahide Nakazawa; Hiroyuki Kitagawa; Wasaburo Koizumi // BMC Research Notes;2014, Vol. 7 Issue 1, p1 

    Background: Pegylated interferon combined with ribavirin treatment is an effective therapy for chronic hepatitis C viral infection. However, pegylated interferon combined with ribavirin is associated with various adverse reactions. Severe thrombocytopenia is a life-threatening side effect of...

  • Developement of lichen planus during pegylated interferon alfa-2B and ribavirin therapy for hepatitis C. Bal, Jasdeep S; Wong, Helen; Prajapati, Devang N // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS205 

    An abstract of the article "Development of Lichen Planus During Pegylated Interferon Alfa-2B and Ribavirin Therapy for Hepatitis C" by Jasdeep S. Bal, Helen Wong, and Devang N. Prajapati is presented.

  • Membranous nephropathy induced by pegylated interferon a-2a therapy for chronic viral hepatitis B. Tsai, Ming.-Shien; Chen, Jui.-Hao; Fang, Yu.-Wei; Yang, An.-Hang; Chang, Chung.-Hsin // Clinical Nephrology;Jun2012, Vol. 77 Issue 6, p496 

    Interferon is used to treat chronic viral hepatitis because of low drug resistance and a high remission rate. However, its propensity to induce and modify autoimmunity has been reported. We used pegylated interferon a-2a to treat a patient with chronic viral hepatitis B. After 5 months of this...


Read the Article


Sign out of this library

Other Topics